Hikal Ltd’s stock tumbled over 6% in early trade after the company announced it received six observations from the US Food and Drug Administration (US FDA) for its Jigani facility in Bengaluru, Karnataka. As of 10:20 AM, the shares were trading 6.30% lower at Rs 353.15.
The regulatory inspection, conducted between February 3 and February 7, 2025, is a routine evaluation to ensure compliance with US FDA guidelines. While the company has not disclosed the specifics of these observations, Hikal has assured stakeholders that it will address the concerns promptly and submit a detailed response within the stipulated timeframe.
Hikal Ltd’s shares opened at ₹370 today, matching the day’s high before slipping to ₹351. The stock remains well below its 52-week high of ₹464.75 but significantly above its low of ₹260.30.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
